Evidence map›Paper›PMID 39595765›Full record

ArticleInternational journal of environmental research and public health2024

Mortality from Hypertrophic Cardiomyopathy in Brazil-Historical Series.

Emerson de Santana Santos, Pedro Henrique Gomes Castro, Laís Prado Smith Lima, João Victor Andrade Pimentel, Gabriel da Costa Kuhn, Antônio Carlos Sobral Sousa, Joselina Luzia Menezes Oliveira

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emerson de Santana SantosDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0000-0002-9175-2210
Pedro Henrique Gomes CastroDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0000-0001-6821-5225
Laís Prado Smith LimaDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0009-0001-0237-4837
João Victor Andrade PimentelDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0000-0002-1884-1495
Gabriel da Costa KuhnDepartment of Medicine, Tiradentes University (UNIT), Aracaju 49032-490, Brazil.ORCID 0009-0009-1532-7368
Antônio Carlos Sobral SousaDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0000-0002-4158-9726
Joselina Luzia Menezes OliveiraDepartment of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.ORCID 0000-0002-4325-0590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is a relatively prevalent disease, primarily of a genetic etiology, affecting both sexes and characterized by left ventricular hypertrophy. However, limitations within healthcare systems, socioracial factors, and the issue of underdiagnosis hinder accurate mortality assessments in our region. This study, therefore, aimed to assess the mortality trends associated with HCM in Brazil from 2010 to 2020, with a focus on socioracial factors and healthcare disparities. This ecological, time-series study employed a quantitative approach based on secondary data from the Mortality System (SIM) developed by the Brazilian Ministry of Health. Mortality incidence and trend analyses were conducted using the average annual percent change (AAPC) and the annual percent change (APC). The results indicated a predominance of HCM-related deaths among white males aged 40 years and older. Additionally, an increasing trend in HCM-related mortality was observed among white and brown males and females aged 40 years and above from 2010 to 2018. Throughout the entire period covered in the study, the incidence of deaths due to HCM increased by 18.3% and 69.8% in the northeastern and southeastern regions. The findings suggest that health system managers should consider addressing the factors influencing HCM mortality and encourage the development and implementation of clinical protocols across healthcare institutions nationwide. Such protocols are recommended to facilitate early diagnosis and establish effective treatment strategies, ultimately aiming to improve the survival rates and quality of life for individuals affected by HCM.

Indexed as

Cardiomyopathy, HypertrophicAdolescentAdultAgedBrazilChildChild, PreschoolFemaleHumansIncidenceMaleMiddle AgedMortalityYoung Adulthypertrophic cardiomyopathymortalitytrends

Identifiers

PMID39595765
PMCPMC11594158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.